Mylan posts quarterly profit compared to year-earlier loss


Aug 6 (Reuters) - Mylan NV MYL.O reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.

The drugmaker reported net earnings of $39.4 million, or 8 cents per share, in the three months ended June 30, compared to a loss of $168.5 million, or 33 cents per share, a year earlier.

Total revenue of the company, whose merger with Pfizer Inc's PFE.N off-patent branded drugs unit has been delayed by the pandemic, fell to $2.73 billion from $2.85 billion.

(Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)

((; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.